CHMP opposes Lilly’s Mounjaro in heart failure, backs Novo’s Kayshild
EU regulators have refused to greenlight Eli Lilly’s weight loss drug Mounjaro as a treatment for a type of heart failure, while giving the go-ahead for Novo Nordisk’s semaglutide in liver disease. Lilly failed to …
First GLP-1 Backed for MASH in Europe
Kayshild is recommended for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis and moderate-to-advanced liver fibrosis. Medscape News Europe
MHRA Warns of Rare Severe Pancreatitis With GLP-1 Drugs
The MHRA has updated safety information for GLP-1 weight-loss and diabetes drugs after rare reports of necrotising and fatal pancreatitis. Medscape News UK
New GLP-1 Weight-Loss Drugs Expected This Year
This Medical News article discusses clinical trial data for weight-loss medications, in both injectable and pill formations, that are currently under review with US Food and Drug Administration.
Bariatric Surgery and GLP-1 Drugs Both Support Sustained Fat Loss
Although bariatric surgery was associated with more evident changes, research found that treatment with glucagon-like peptide-1 (GLP-1) medications was also associated with sustained fat loss in a clinical setting.
FDA Requests Removal of Suicidal Ideation Warning From GLP-1 RA Medications
The US Food and Drug Administration (FDA) requested that drug application holders remove suicidal ideation and behavior warnings from glucagon-like peptide-1 (GLP-1) receptor agonists.
IJMS, Vol. 27, Pages 1409: Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes
IJMS, Vol. 27, Pages 1409: Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes International Journal of Molecular Sciences doi: 10.3390/ijms27031409 Authors: Urna Kansakar Stanislovas S. Jankauskas Shivangi Pande Pasquale Mone Fahimeh Varzideh Gaetano Santulli Orforglipron (LY3502970) is a novel, orally available, nonpeptide glucagon-like peptide-1 receptor agonist […]
Heart Failure Data Added to GLP-1 Prescribing Info
Mounjaro significantly reduced hospitalizations in adults with obesity and symptomatic chronic heart failure with preserved ejection fraction. Medscape News Europe
GLP-1 Weight Loss Drugs and the ‘Exploding Colon’ Lawsuits: A Symptom of a Deeper Health Crisis
(NaturalNews) IntroductionA seismic shift in American health culture is being violently undone in courtrooms across the nation. The blockbuster GLP-1 weight-loss …
OZEM Vs. THNR: Which Is The Better ETF In The GLP-1 And Weight Loss Space?
Post Content